Gasparro Donatello, Scarlattei Maura, Manuguerra Roberta, Guglielmo Priscilla, Migliari Silvia, Sammartano Antonino, Baldari Giorgio, Maestroni Umberto, Silini Enrico Maria, Ruffini Livia
From the Oncology Division.
Nuclear Medicine Unit.
Clin Nucl Med. 2021 Sep 1;46(9):e458-e460. doi: 10.1097/RLU.0000000000003660.
Renal cell carcinoma (RCC) shows variable FDG uptake; recently, PET/CT with prostate-specific membrane antigen (PSMA)-target radiotracers was demonstrated to be a promising tool in staging and restaging of RCC patients. We describe the case of a 77-year-old man with a lung metastasis of papillary RCC missed by CT scan who successfully underwent [18F]FDG PET/CT restaging. Targeted therapy with sunitinib was administered. A [68Ga]PSMA PET/CT performed during follow-up demonstrated, among the already known lesions, also a bone marrow metastasis, missed by previous CT scans. This case demonstrates that PET/CT molecular imaging with [18F]FDG and [68Ga]PSMA is superior to conventional imaging in RCC restaging and in assessing therapy response.
肾细胞癌（RCC）的氟代脱氧葡萄糖（FDG）摄取情况各异；最近，正电子发射断层扫描/计算机断层扫描（PET/CT）联合前列腺特异性膜抗原（PSMA）靶向放射性示踪剂被证明是RCC患者分期及再分期的一种有前景的工具。我们描述了一例77岁男性乳头状RCC肺转移患者，其肺部转移灶被CT扫描漏诊，后成功接受了[18F]FDG PET/CT再分期检查。给予舒尼替尼靶向治疗。随访期间进行的[68Ga]PSMA PET/CT检查显示，在已知病灶中，还有一处骨髓转移灶，之前的CT扫描未发现。该病例表明，[18F]FDG和[68Ga]PSMA的PET/CT分子成像在RCC再分期及评估治疗反应方面优于传统成像。
